Table 2.
Linear mixed-effects regression models of T cell (IFNγ) or Ab (IgG) immune responses
| S T cell responses in naive participants | S T cell responses in pre inf participants | S Ab responses in naive participants | S Ab responses in pre inf participants | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coefficient | Estimates | CI (95%) | p Value | Estimates | CI (95%) | p Value | Estimates | CI (95%) | p Value | Estimates | CI (95%) | p Value | ||
| Intercept | 1.47 | 0.95–1.98 | <0.001a | 1.92 | 1.26–2.59 | <0.001a | 4.84 | 4.42–5.26 | <0.001a | 5.77 | 5.41–6.12 | <0.001a | ||
| Age | −0.00 | −0.02 to 0.01 | 0.705 | 0.01 | −0.01 to 0.02 | 0.480 | −0.01 | −0.02 to 0.00 | 0.090 | −0.00 | −0.01 to 0.01 | 0.640 | ||
| Sex (M) | −0.15 | −0.54 to 0.23 | 0.435 | 0.42 | 0.01–0.84 | 0.046a | 0.09 | −0.26 to 0.45 | 0.608 | −0.04 | 0.29 to 0.21 | 0.757 | ||
| Time point (pre vaccine) | −0.79 | −1.08 to −0.50 | <0.001a | −0.88 | −1.09 to −0.67 | <0.001a | −2.79 | −2.95 to −2.63 | <0.001a | −1.65 | −1.77 to −1.54 | <0.001a | ||
| Time point (dose 1 + 10 weeks) | 0.28 | −0.01 to 0.57 | 0.060 | 0.08 | −0.13 to 0.28 | 0.466 | −0.38 | −0.53 to −0.22 | < 0.001a | −0.18 | −0.29 to −0.07 | 0.002a | ||
| Time point (dose 2 + 4 weeks) | 0.85 | 0.56–1.13 | <0.001a | 0.31 | 0.10–0.51 | 0.003a | 0.97 | 0.81–1.12 | <0.001a | −0.02 | −0.13 to 0.10 | 0.793 | ||
| Random effects | ||||||||||||||
| σ2 | 0.28 | 0.14 | 0.09 | 0.05 | ||||||||||
| τ00 | 0.06 PubID | 0.12 PubID | 0.09 PubID | 0.04 PubID | ||||||||||
| ICC | 0.18 | 0.46 | 0.49 | 0.43 | ||||||||||
| N | 26 PubID | 26 PubID | 29 PubID | 29 PubID | ||||||||||
| Observations | 103 | 104 | 116 | 116 | ||||||||||
| Marginal R2/conditional R2 | 0.506/0.593 | 0.462/0.710 | 0.914/0.956 | 0.848/0.913 | ||||||||||
Shown are four linear mixed-effect regression models (LMERs) of T cell or Ab responses in naive or pre-inf individuals across vaccine time points in the long vaccine dose regimen. Variables include age, sex, and time point. Variable references are sex (F [female] versus M [male]), time point (dose 1 + 4 weeks versus pre-vaccine/dose 1 + 10 weeks/dose 2 + 4 weeks.
Indicates statistical significance.